{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:25:29Z","timestamp":1792297529607,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>More than 0.6 million people suffer from disabling migraines in Greece causing a dramatic work loss, but only a small proportion of migraineurs attend headache centres, most of them being treated by non-experts. On behalf of the Hellenic Headache Society, we report here a consensus on the diagnosis and treatment of adult migraine that is based on the recent guidelines of the European Headache Federation, on the principles of Good Clinical Practice and on the Greek regulatory affairs. The purposes are three-fold: (1) to increase awareness for migraine in Greece; (2) to support Greek practitioners who are treating migraineurs; and (3) to help Greek migraineurs to get the most appropriate treatment. For mild migraine, symptomatic treatment with high dose simple analgesics is suggested, while for moderate to severe migraines triptans or non-steroidal anti-inflammatory drugs, or both, should be administered following an individually tailored therapeutic strategy. A rescue acute treatment option should always be advised. For episodic migraine prevention, metoprolol (50\u2013200\u2009mg\/d), propranolol (40\u2013240\u2009mg\/d), flunarizine (5\u201310\u2009mg\/d), valproate (500\u20131800\u2009mg\/d), topiramate (25\u2013100\u2009mg\/d) and candesartan (16\u201332\u2009mg\/d) are the drugs of first choice. For chronic migraine prevention topiramate (100-200\u2009mg\/d), valproate (500\u20131800\u2009mg\/d), flunarizine (5\u201310\u2009mg\/d) and venlafaxine (150\u2009mg\/d) may be used, but the evidence is very limited. Botulinum toxin type A and monoclonal antibodies targeting the CGRP pathway (anti-CGRP mAbs) are recommended for patients suffering from chronic migraine (with or without medication overuse) who failed or did not tolerate two previous treatments. Anti-CGRP mAbs are also suggested for patients suffering from high frequency episodic migraine (\u22658 migraine days per month and less than 14) who failed or did not tolerate two previous treatments.<\/jats:p>","DOI":"10.1186\/s10194-019-1060-6","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T17:03:48Z","timestamp":1576256628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine"],"prefix":"10.1186","volume":"20","author":[{"name":"Hellenic Headache Society","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Kouremenos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysa","family":"Arvaniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros S.","family":"Constantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermioni","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Kalamatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Kararizou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Naoumis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos D.","family":"Mitsikostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954\u2013976","journal-title":"Lancet Neurol"},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","volume":"19","author":"T Steiner","year":"2018","unstructured":"Steiner T, Lars J, Stovner LJ, Theo Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19:17\u201320","journal-title":"J Headache Pain"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, Lainez JM, Lampl C, Lant\u00e9ri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andr\u00e9e C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703\u2013711","journal-title":"Eur J Neurol"},{"issue":"Suppl 15","key":"1060_CR4","doi-asserted-by":"crossref","first-page":"P3.143","DOI":"10.1212\/WNL.90.15_supplement.P3.143","volume":"90","author":"DD Mitsikostas","year":"2018","unstructured":"Mitsikostas DD, Arvaniti C, Constantinidis T, Fakas N, Dermitzakis E, Rudolf J, Vikelis M (2018) A population based survey for headaches in Greece to estimate prevalence and treatment preferences. Neurology 90(Suppl 15):P3.143","journal-title":"Neurology"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-016-0596-y","volume":"17","author":"DD Mitsikostas","year":"2015","unstructured":"Mitsikostas DD, Ashina M, Craven A, Diener HC, Goadsby PJ, Ferrari MD, Lampl C, Paemeleire K, Pascual J, Siva A, Olesen J, Osipova V, Martelletti P, EHF committee (2015) European Headache Federation consensus on technical investigation for primary headache disorders. J Headache Pain 17:5","journal-title":"J Headache Pain"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 20:6","journal-title":"J Headache Pain."},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, Martelletti P (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 19:91","journal-title":"J Headache Pain"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, S\u00e1ndor PS, European Federation of Neurological Societies (2009) EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 16:968\u2013981","journal-title":"Eur J Neurol"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1468-1331.2011.03497.x","volume":"18","author":"S Evers","year":"2011","unstructured":"Evers S, Jensen R, European Federation of Neurological Societies (2011) Treatment of medication overuse headache--guideline of the EFNS headache panel. Eur J Neurol 18:1115\u20131121","journal-title":"Eur J Neurol"},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-017-0813-3","volume":"18","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Belesioti I, Arvaniti C, Mitropoulou E, Deligianni C, Kasioti E, Constantinidis T, Dermitzakis M, Vikelis M, Hellenic Headache Society (2017) Patients\u2019 preferences for headache acute and preventive treatment. J Headache Pain 18:102","journal-title":"J Headache Pain"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1468-2982.1999.019004211.x","volume":"19","author":"DD Mitsikostas","year":"1999","unstructured":"Mitsikostas DD, Thomas A (1999) Comorbidity of headache and depressive disorders. Cephalalgia 19:211\u2013217","journal-title":"Cephalalgia"},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s41669-017-0034-3","volume":"2","author":"T Oikonomidi","year":"2018","unstructured":"Oikonomidi T, Vikelis M, Artemiadis A, Chrousos GP, Darviri C (2018) Reliability and validity of the Greek migraine disability assessment (MIDAS) questionnaire. Pharmacoecon Open 2:77\u201385","journal-title":"Pharmacoecon Open"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/mpr.10","volume":"14","author":"I Kavasis","year":"2005","unstructured":"Kavasis I, Samakouri M, Mallis D, Terzoudi A, Papanastassiou E, Tzavaras N, Livaditis M (2005) Translation and validation of the depression outcomes module (DOM) in Greece. Int J Methods Psychiatr Res 14:221\u2013229","journal-title":"Int J Methods Psychiatr Res"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1023\/A:1026163113446","volume":"12","author":"JB Bjorner","year":"2003","unstructured":"Bjorner JB, Kosinski M, Ware JE Jr (2003) Calibration of an item pool for assessing the burden of headaches: an application of item response theory to the headache impact test (HIT). Qual Life Res 12:913\u2013933","journal-title":"Qual Life Res"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1468-2982.2009.02017.x","volume":"30","author":"DD Mitsikostas","year":"2010","unstructured":"Mitsikostas DD, Vikelis M, Kodounis A, Zaglis D, Xifaras M, Doitsini S, Georgiadis G, Thomas A, Charmoussi S (2010) Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. Cephalalgia. 30:690\u2013695","journal-title":"Cephalalgia."},{"key":"1060_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1468-2982.1994.1405330.x","volume":"14","author":"MD Ferrari","year":"1994","unstructured":"Ferrari MD, James MH, Bates D et al (1994) Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14:330\u2013338","journal-title":"Cephalalgia"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","volume":"297","author":"JL Brandes","year":"2007","unstructured":"Brandes JL, Kudrow D, Stark SR, O\u2019Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE (2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 297:1443\u20131454","journal-title":"JAMA."},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/01.wnl.0000316800.22949.20","volume":"71","author":"SD Silberstein","year":"2008","unstructured":"Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH, McDonald SA, Lener SE, Toso C (2008) Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 71:114\u2013121","journal-title":"Neurology."},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3810\/pgm.2014.03.2743","volume":"126","author":"AH Calhoun","year":"2014","unstructured":"Calhoun AH, Ford S (2014) Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85\/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it? Postgrad Med 126:86\u201390","journal-title":"Postgrad Med"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0333102416660552","volume":"37","author":"K Thorlund","year":"2017","unstructured":"Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, Bhambri R, Donnet A, Stark R, Goadsby PJ (2017) Comparative tolerability of treatments for acute migraine: A network meta-analysis. Cephalalgia. 37:965\u2013978","journal-title":"Cephalalgia."},{"key":"1060_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10194-005-0169-y","volume":"6","author":"Z Engindeniz","year":"2005","unstructured":"Engindeniz Z, Demircan C, Karli N, Armagan E, Bulut M, Aydin T, Zarifoglu M (2005) Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. J Headache Pain. 6:143\u2013148","journal-title":"J Headache Pain."},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"e0120229","DOI":"10.1371\/journal.pone.0120229","volume":"10","author":"S Mazaheri","year":"2015","unstructured":"Mazaheri S, Poorolajal J, Hosseinzadeh A, Fazlian MM (2015) Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial. PLoS One 10:e0120229","journal-title":"PLoS One"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1526-4610.2005.00264.x","volume":"45","author":"SD Silberstein","year":"2005","unstructured":"Silberstein SD, Freitag FG, Rozen TD, Hewitt DJ, Jordan DM, Fisher AC, Rosenthal NR (2005) Tramadol\/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache 45:1317\u20131327","journal-title":"Headache"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/ane.13063","volume":"139","author":"N\u00d6 Do\u011fan","year":"2019","unstructured":"Do\u011fan N\u00d6, Pekdemir M, Y\u0131lmaz S, Yaka E, Karada\u015f A, Durmu\u015f U, Avcu N, Ko\u00e7kan E (2019) Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial. Acta Neurol Scand 139:334\u2013339","journal-title":"Acta Neurol Scand"},{"key":"1060_CR26","doi-asserted-by":"publisher","unstructured":"Kirthi V, Derry S, Moore RA (2013) Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev (4):CD008041. https:\/\/doi.org\/10.1002\/14651858.CD008041.pub3","DOI":"10.1002\/14651858.CD008041.pub3"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/head.12835","volume":"56","author":"SL Orr","year":"2016","unstructured":"Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (2016) Management of Adults with Acute Migraine in the emergency department: the American headache society evidence assessment of parenteral pharmacotherapies. Headache. 56:911\u2013940","journal-title":"Headache."},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/WCO.0b013e328352c416","volume":"25","author":"CI Deligianni","year":"2012","unstructured":"Deligianni CI, Vikelis M, Mitsikostas DD (2012) Depression in headaches: chronification. Curr Opin Neurol 25:277\u2013283","journal-title":"Curr Opin Neurol"},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.289.1.65","volume":"289","author":"E Tronvik","year":"2003","unstructured":"Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 289:65\u201369","journal-title":"JAMA."},{"key":"1060_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0333102413515348","volume":"34","author":"LJ Stovner","year":"2014","unstructured":"Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K (2014) A comparative study of candesartan versus propranolol for migraineprophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 34:523\u2013532","journal-title":"Cephalalgia."},{"key":"1060_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","volume":"49","author":"S Silberstein","year":"2009","unstructured":"Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 49:1153\u20131162","journal-title":"Headache."},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0333102410372427","volume":"31","author":"RB Lipton","year":"2011","unstructured":"Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J (2011) Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 31:18\u201330","journal-title":"Cephalalgia."},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.pnpbp.2011.01.016","volume":"35","author":"A Mowla","year":"2011","unstructured":"Mowla A, Kardeh E (2011) Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial. Prog Neuro-Psychopharmacol Biol Psychiatry 35:970\u2013973","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1060_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/YIC.0000000000000097","volume":"31","author":"ED Peselow","year":"2016","unstructured":"Peselow ED, Clevenger S, IsHak WW (2016) Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study. Int Clin Psychopharmacol 31:218\u2013223","journal-title":"Int Clin Psychopharmacol"},{"key":"1060_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2019.06.031","volume":"98","author":"M Bosak","year":"2019","unstructured":"Bosak M, S\u0142owik A, Turaj W (2019) Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. Epilepsy Behav 98:1\u20135","journal-title":"Epilepsy Behav"},{"key":"1060_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ane.12626","volume":"135","author":"KL Lai","year":"2017","unstructured":"Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT, Wu JC, Wang SJ (2017) Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand 135:476\u2013483","journal-title":"Acta Neurol Scand"},{"key":"1060_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, Hirtz D, Chronic Migraine Treatment Trial Research Group (2012) Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 78:976\u2013984","journal-title":"Neurology"},{"key":"1060_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/WCO.0000000000000438","volume":"30","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 30:272\u2013280","journal-title":"Curr Opin Neurol"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12916-015-0522-1","volume":"13","author":"DD Mitsikostas","year":"2015","unstructured":"Mitsikostas DD, Rapoport AM (2015) New players in the preventive treatment of migraine. BMC Med 13:279","journal-title":"BMC Med"},{"key":"1060_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/ene.12393","volume":"21","author":"HC Diener","year":"2014","unstructured":"Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF (2014) Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol 21:851\u2013859","journal-title":"Eur J Neurol"},{"key":"1060_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"HC Diener","year":"2019","unstructured":"Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T (2019) Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 18:891\u2013902","journal-title":"Lancet Neurol"},{"key":"1060_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1468-2982.2007.01300.x","volume":"27","author":"NP Zissis","year":"2007","unstructured":"Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, Karageorgiou K (2007) A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia. 27:315\u2013324","journal-title":"Cephalalgia."},{"key":"1060_CR43","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1468-1331.2010.03070.x","volume":"17","author":"L Bendtsen","year":"2010","unstructured":"Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J, EFNS (2010) EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 17:1318\u20131325","journal-title":"Eur J Neurol"},{"key":"1060_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1129-2377-14-86","volume":"14","author":"P Martelletti","year":"2013","unstructured":"Martelletti P, Jensen RH, Antal A, Arcioni R, Brighina F, de Tommaso M, Franzini A, Fontaine D, Heiland M, J\u00fcrgens TP, Leone M, Magis D, Paemeleire K, Palmisani S, Paulus W, May A, European Headache Federation (2013) Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain 14:86","journal-title":"J Headache Pain"},{"key":"1060_CR45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jnnp-2018-320113","volume":"90","author":"U Reuter","year":"2019","unstructured":"Reuter U, McClure C, Liebler E, Pozo-Rosich P (2019) Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J Neurol Neurosurg Psychiatry 90:796\u2013804","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1060_CR46","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1212\/WNL.0000000000005857","volume":"91","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, Dorlas S, Geppetti P, Ambrosini A, Sarchielli P, Liebler E, Barbanti P, PRESTO Study Group (2018) Non-invasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology. 91:e364\u2013e373","journal-title":"Neurology."},{"key":"1060_CR47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/head.13479","volume":"59","author":"JM Stilling","year":"2019","unstructured":"Stilling JM, Monchi O, Amoozegar F, Debert CT (2019) Transcranial Magnetic and Direct Current Stimulation (TMS\/tDCS) for the Treatment of Headache: A Systematic Review. Headache. 59:339\u2013357","journal-title":"Headache."},{"key":"1060_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0333102418811573","volume":"39","author":"DE Chou","year":"2019","unstructured":"Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J (2019) Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia. 39:3\u201314","journal-title":"Cephalalgia."},{"key":"1060_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","volume":"80","author":"J Schoenen","year":"2013","unstructured":"Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, G\u00e9rard P, Magis D (2013) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 80:697\u2013704","journal-title":"Neurology."},{"key":"1060_CR50","doi-asserted-by":"publisher","unstructured":"Rehman T, Ahmad S, Fatima Q (2019) Effects of dietary supplementations and herbs on migraine - a systematic review. J Complement Integr Med. 16(3). https:\/\/doi.org\/10.1515\/jcim-2018-0143","DOI":"10.1515\/jcim-2018-0143"},{"key":"1060_CR51","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ana.24534","volume":"78","author":"C Buettner","year":"2015","unstructured":"Buettner C, Nir RR, Bertisch SM, Bernstein C, Schain A, Mittleman MA, Burstein R (2015) Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol 78:970\u2013981","journal-title":"Ann Neurol"},{"key":"1060_CR52","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/0333102410391485","volume":"31","author":"DD Mitsikostas","year":"2011","unstructured":"Mitsikostas DD, Mantonakis LI, Chalarakis NG (2011) Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 31:550\u2013561","journal-title":"Cephalalgia."},{"key":"1060_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/WCO.0000000000000313","volume":"29","author":"DD Mitsikostas","year":"2016","unstructured":"Mitsikostas DD (2016) Nocebo in headache. Curr Opin Neurol 29:331\u2013336","journal-title":"Curr Opin Neurol"},{"key":"1060_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-019-0965-4","volume":"20","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Lee JH, Cho EY, Kim SM, Yoon S (2019) Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J Headache Pain. 20:17","journal-title":"J Headache Pain."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1060-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-019-1060-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1060-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T16:02:07Z","timestamp":1722182527000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-019-1060-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1186\/s10194-019-1060-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"20 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent to participate was not needed for this consensus.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the final version and gave their approval for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}